What is Migraine?
Migraine Pathophysiology and the Role of CGRP
Therapeutic Monoclonal Antibodies: A Review
Eptinezumab-jjmr Antibody Science: Pharmacokinetics and MOA
VYEPTI® (eptinezumab-jjmr) in Migraine Prevention: Clinical and Safety Data
VYEPTI® (eptinezumab-jjmr) in Migraine Prevention: Safety and Dosing
VYEPTI is indicated for the preventive treatment of migraine in adults.
Important Safety Information
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
WARNINGS AND PRECAUTIONS
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.